CARMIEL, Israel , May 23, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell–based protein

Milestone payment triggered by FDA approval of ELFABRIO ®  (pegunigalsidase alfa-iwxj) and payable within 30 days of approval CARMIEL, Israel , May 18, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and

- PEGylated enzyme replacement therapy designed to provide long half-life* - BOSTON and CARMIEL, Israel , May 10, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, and

- PEGylated enzyme replacement therapy designed to provide a long half-life - PARMA, Italy , BOSTON and CARMIEL, Israel , May 5, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , May 4, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced

Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , April 27, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by

PRX-115 is a PEGylated recombinant uricase produced from the proprietary ProCellEx ®  platform as a potential treatment of severe gout CARMIEL, Israel , March 21, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the

CARMIEL, Israel , March 13, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell based

Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel , Feb. 27, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic

- European Commission decision anticipated in beginning of May 2023 - PARMA, Italy and BOSTON and CARMIEL, Israel , Feb. 24, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare